WisdomTree International MidCap Dividend Fund (DIM)
Live price chart, market sentiment, and community perspectives for WisdomTree International MidCap Dividend Fund (AMEX: DIM).
Live price chart, market sentiment, and community perspectives for WisdomTree International MidCap Dividend Fund (AMEX: DIM).
On our desk, we are monitoring the recent valuation metrics for the WisdomTree International MidCap Dividend Fund (DIM), which recently closed at $87.17. Market sentiment appears neutral to stable, underscored by a Danelfin AI score sitting right at 5/10 with a designated low-risk categorization. For positioning, the overarching market vibe suggests that while it provides targeted exposure to ex-U.S. dividend-paying mid-cap companies, traders must weigh its 0.58% annual expense ratio against prevailing macroeconomic conditions in the developed world. We advise keeping a close watch on these structural portfolio costs before expanding allocations.
Looking at the quantitative risk profile for DIM, short interest is remarkably muted, standing at just 7,655 shares sold short as of late June 2026. This accounts for a mere 0.40% of the public float, indicating a near-total absence of aggressive bearish positioning or downward speculative pressure from short sellers. Quantitatively, this low short interest reinforces the fund's low-risk baseline flagged by algorithmic models, signaling that market participants are currently holding positions rather than betting against the underlying basket of developed market mid-cap dividend equities.
When evaluating multi-asset portfolios focused on international mid-cap income strategies, candidates should understand the explicit tracking mandate of funds like DIM. The fund specifically tracks dividend-paying mid-cap corporations located in the developed world, excluding the United States. During technical evaluations or portfolio construction reviews, it is vital to articulate how incorporating ex-U.S. mid-caps affects overall yield distribution, and how tracking error against broad international benchmarks is managed. Keep the 0.58% expense fee in mind as a baseline hurdle for alpha generation relative to lower-cost broad-market alternatives.
Explore plasma cleansing, somatic organ swaps, and BCI.